IRR-401

IRR-401 is an investigational proprietary oral fixed-dose combination of **levocetirizine** and **montelukast** developed by Inflammatory Response Research for COVID-19. Levocetirizine inhibits histamine H1 receptor signaling, while montelukast selectively antagonizes cysteinyl leukotriene receptor 1, together suppressing histamine- and leukotriene-mediated inflammatory activity. IRR reported a Phase 1 pilot study in COVID-19-positive patients and proposed subsequent randomized Phase 2 evaluation; the underlying components are separately approved drugs for other indications. ([businesswire.com](https://www.businesswire.com/news/home/20220215005256/en/Inflammatory-Response-Research-Announces-Positive-Data-from-Phase-1-Pilot-Study-of-IRR-401-in-COVID-Patients))

Other names

levocetirizine + montelukastlevocetirizine/montelukastmontelukast + levocetirizinemontelukast/levocetirizine